CR10566A - Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos - Google Patents

Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos

Info

Publication number
CR10566A
CR10566A CR10566A CR10566A CR10566A CR 10566 A CR10566 A CR 10566A CR 10566 A CR10566 A CR 10566A CR 10566 A CR10566 A CR 10566A CR 10566 A CR10566 A CR 10566A
Authority
CR
Costa Rica
Prior art keywords
lipids
appropriate
treatment
diseases related
elevated level
Prior art date
Application number
CR10566A
Other languages
English (en)
Inventor
Natalie Dales
Julia Fonarev
Jianmin Fu
Rajender Kamboj
Vishnumurthy Kodumuru
Shifeng Liu
Natalia Pokrovskaia
Vandna Raina
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10566(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10566A publication Critical patent/CR10566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invencion porporciona derivados heterociclicos que modulan la actividad de la estearoil-CoA-desaturasa. Tambien se abarcan metodos para utilizar estos derivados, con el fin de modular la actividad de la estearoil-CoA-desaturasa, y composiciones farmaceuticas que comprenden estos derivados.
CR10566A 2006-08-15 2009-01-16 Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos CR10566A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82245906P 2006-08-15 2006-08-15

Publications (1)

Publication Number Publication Date
CR10566A true CR10566A (es) 2009-03-11

Family

ID=39864516

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10566A CR10566A (es) 2006-08-15 2009-01-16 Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos

Country Status (27)

Country Link
US (2) US8063084B2 (es)
EP (1) EP2054408B1 (es)
JP (1) JP4972690B2 (es)
KR (4) KR20110077006A (es)
CN (1) CN101535303B (es)
AR (1) AR062360A1 (es)
AU (1) AU2007351498B2 (es)
BR (1) BRPI0716407A2 (es)
CA (1) CA2660201C (es)
CL (1) CL2007002348A1 (es)
CO (1) CO6241156A2 (es)
CR (1) CR10566A (es)
ES (1) ES2597453T3 (es)
GT (1) GT200900027A (es)
IL (1) IL196562A0 (es)
MA (1) MA30655B1 (es)
MX (1) MX2009001634A (es)
MY (1) MY153263A (es)
NO (1) NO20091083L (es)
NZ (2) NZ574222A (es)
PE (3) PE20110341A1 (es)
RU (1) RU2009109147A (es)
TN (1) TN2009000045A1 (es)
TW (1) TWI404718B (es)
UA (1) UA96766C2 (es)
WO (1) WO2008127349A2 (es)
ZA (1) ZA200900263B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660201C (en) 2006-08-15 2016-05-03 Novartis Ag Organic compounds
BRPI0720452A2 (pt) * 2006-12-20 2014-01-14 Novartis Ag Compostos orgânicos
BRPI0815979A2 (pt) 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
AU2013200845B2 (en) * 2008-02-20 2015-01-29 Xenon Pharmaceuticals Inc. Heterocyclic inhibitors of stearoyl-CoA desaturase
NZ587350A (en) * 2008-02-20 2012-07-27 Novartis Ag Thiazole derivatives featuring an imidazolidine or triazole derivative as inhibitors of stearoyl-CoA desaturase
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
WO2010094120A1 (en) 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EA201200545A1 (ru) * 2009-10-01 2012-12-28 Новартис Аг Производные пиразола, которые модулируют стеароил-соа десатуразу
US9296719B2 (en) * 2011-07-08 2016-03-29 Indiana University Research And Technology Corporation Compositions and methods for the treatment of norovirus infection
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
WO2013175474A2 (en) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
US9181261B2 (en) * 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
CA2921420A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201608710TA (en) * 2014-04-28 2016-11-29 Jiangsu Kanion Parmaceutical Co Ltd Anti-enterovirus 71 thiadiazolidine derivative
DK3277286T3 (da) 2015-03-31 2021-07-05 Enanta Pharm Inc Galdesydererivater som fxr/tgr5-agonister og anvendelsesmetoder deraf
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2018067704A1 (en) * 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
EP3566055A4 (en) 2017-01-06 2020-12-02 Yumanity Therapeutics, Inc. TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
CN115286616A (zh) * 2022-07-27 2022-11-04 北京师范大学 结合sigma-2受体的四氢异喹啉和异吲哚啉类化合物、其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245971B (de) * 1962-05-30 1967-08-03 Ciba Aktiengesellschaft, Basel (Schweiz) Verfahren zur Herstellung von neuen Tetrahydro-imidazolen
CH455806A (de) * 1963-08-30 1968-05-15 Ciba Geigy Verfahren zur Herstellung neuer Imidazole
CH463517A (de) * 1964-04-24 1968-10-15 Ciba Geigy Verfahren zur Herstellung neuer Diazacycloalkanverbindungen
US4058617A (en) * 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
CH590267A5 (es) * 1972-10-04 1977-07-29 Ciba Geigy Ag
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
NZ184081A (en) * 1976-06-01 1980-10-08 Velsicol Chemical Corp 1-thiazol-2-yl-1 3-imidazolidn-2-ones
US4086240A (en) * 1976-06-01 1978-04-25 Velsicol Chemical Corporation 1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones
US4116969A (en) 1976-06-01 1978-09-26 Velsicol Chemical Company 1-thiazolyl-5-hydroxyimidazolidinones
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
JP2002515014A (ja) * 1995-05-17 2002-05-21 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性の環式アミド類
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
AU2001247228B2 (en) 2000-02-24 2007-01-18 Wisconsin Alumni Research Foundation Stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
DK1390340T3 (en) 2001-04-24 2017-05-15 Massachusetts Inst Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
CA2450400A1 (en) 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
AU2003256755A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
WO2005077937A1 (en) 2004-01-09 2005-08-25 Cadila Healthcare Limited Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
CN101460476B (zh) 2006-06-05 2013-12-04 诺瓦提斯公司 有机化合物
CA2660201C (en) 2006-08-15 2016-05-03 Novartis Ag Organic compounds
MX2009002019A (es) 2006-08-24 2009-03-09 Novartis Ag Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
EP2066664A1 (en) 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
BRPI0720452A2 (pt) 2006-12-20 2014-01-14 Novartis Ag Compostos orgânicos
NZ587350A (en) 2008-02-20 2012-07-27 Novartis Ag Thiazole derivatives featuring an imidazolidine or triazole derivative as inhibitors of stearoyl-CoA desaturase
MX2010014572A (es) 2008-06-27 2011-03-24 Novartis Ag Compuestos organicos.

Also Published As

Publication number Publication date
JP2010501488A (ja) 2010-01-21
AR062360A1 (es) 2008-11-05
ES2597453T3 (es) 2017-01-18
EP2054408B1 (en) 2016-07-13
PE20110371A1 (es) 2011-06-24
TWI404718B (zh) 2013-08-11
KR20090040385A (ko) 2009-04-23
US8063084B2 (en) 2011-11-22
PE20110341A1 (es) 2011-06-21
CO6241156A2 (es) 2011-01-20
KR20130036080A (ko) 2013-04-09
WO2008127349A3 (en) 2009-02-12
GT200900027A (es) 2010-06-01
NZ574222A (en) 2012-03-30
MX2009001634A (es) 2009-02-25
NZ598548A (en) 2013-09-27
CN101535303A (zh) 2009-09-16
CL2007002348A1 (es) 2008-08-08
EP2054408A2 (en) 2009-05-06
TN2009000045A1 (en) 2010-08-19
AU2007351498A1 (en) 2008-10-23
CA2660201A1 (en) 2008-10-23
AU2007351498B2 (en) 2012-04-05
KR20110077006A (ko) 2011-07-06
TW200815427A (en) 2008-04-01
CA2660201C (en) 2016-05-03
US8293768B2 (en) 2012-10-23
US20120004164A1 (en) 2012-01-05
IL196562A0 (en) 2009-11-18
CN101535303B (zh) 2012-07-18
MY153263A (en) 2015-01-29
NO20091083L (no) 2009-04-28
UA96766C2 (ru) 2011-12-12
PE20081316A1 (es) 2008-10-16
KR20140019873A (ko) 2014-02-17
MA30655B1 (fr) 2009-08-03
BRPI0716407A2 (pt) 2014-05-20
US20100233116A1 (en) 2010-09-16
RU2009109147A (ru) 2010-09-27
ZA200900263B (en) 2011-11-30
WO2008127349A2 (en) 2008-10-23
JP4972690B2 (ja) 2012-07-11

Similar Documents

Publication Publication Date Title
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
ECSP11010787A (es) Compuestos orgánicos
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
MX2009010170A (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
CR11629A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA- DESATURASA.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201170832A1 (ru) Пуриновые соединения
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
CU23421A3 (es) Derivados de diazepinoindol como inhibidores de quinasa
CU20120052A7 (es) Derivados de pirazol que modulan estearoil-coa-desaturasa
CU20060152A7 (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
PA8622201A1 (es) Derivados de indazol como inhibidores de la lipasa sensible a hormonas
UY29539A1 (es) Inhibidores heterociclicos de mek y metodos de uso de los mismos
CR9238A (es) Pirrolopirazoles, potentes inhibidores de cinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)